Pharmacogenomics and the (ir)relevance of race

Pharmacogenomics and the (ir)relevance of race


Play all audios:

Loading...

Access through your institution Buy or subscribe Race,Footnote 1 as opposed to ethnicity, is a predictor of questionable value for differences in susceptibility to, and pathogenesis of,


disease susceptibility. As social constructs, however, both race and ethnicity are powerful organizing forces employed both by those who use differences to stigmatize and those who view


differences as a source of pride, community, and shared history. Even as society acknowledges that humans are more alike than different, efforts to eliminate race in medical research are met


with as much suspicion as those attempts to employ race in research design. In some instances, the opposition to abandon racial categories has come from those groups who have historically


suffered poor treatment or stigma based on race. History has bred distrust among historically disfavored population groups of the possible agendas of those who would now abandon racial


categories as a marker or measuring stick for any purpose. For purposes of this discussion, the term ‘race’ is defined as ‘a distinct ethnic group characterized by traits that are


transmitted through their offspring’. An ethnic group is ‘a social group or category of the population that, in a larger society, is set apart and bound together by common ties of race,


language, nationality or culture’. Census, Race and Science. _Nat Genet_ 2000; 24: 97–98. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through


your institution Subscribe to this journal Receive 6 print issues and online access $259.00 per year only $43.17 per issue Learn more Buy this article * Purchase on SpringerLink * Instant


access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions *


Read our FAQs * Contact customer support NOTES * For purposes of this discussion, the term ‘race’ is defined as ‘a distinct ethnic group characterized by traits that are transmitted through


their offspring’. An ethnic group is ‘a social group or category of the population that, in a larger society, is set apart and bound together by common ties of race, language, nationality or


culture’. Census, Race and Science. _Nat Genet_ 2000; 24: 97–98. * ‡Ultimately, the aim of pharmacogenomics is to enable physicians to tailor drug therapy to the individual based on that


individual’s genotype. REFERENCES * Reference deleted in proof * RS Schwartz . Racial profiling in medical research _N Eng J Med_ 2001 344: 1392–1393 Article  CAS  Google Scholar  * J Gu _et


al_. Ethnic differences in poly CADP-ribose polymerase pseudogene genotype distribution association with lung cancer risk _Carcinogenesis_ 1999 20: 1465–1469 Article  CAS  Google Scholar  *


CM Stein _et al_ . Hypertension in black people: study of specific genotypes and phenotypes will provide a greater understanding of interindividual and interethnic variability in blood


pressure regulation than studies based on race _Pharmacogenetics_ 2001 11: 95–110 Article  CAS  Google Scholar  * S Olson . Genetic archaeology of race _Atl Monthly_ 2001 287: 69–80 Google


Scholar  * Reference deleted in proof * MM Shi _et al_. Pharmacogenetic application in drug development and clinical trials _Drug Metab Dispos_ 2001 29: 591–595 CAS  PubMed  Google Scholar 


* J Hanke . _Genomics and new technologies as catalysts for change in the drug discovery paradigm_ Whitehead Policy Symposium 2000 Google Scholar  * WW Weber . _Pharmacogenetics_ Oxford


University Press: New York 1997 Google Scholar  * EJ Carlini _et al_. Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects


_Pharmacogenetics_ 2001 11: 57–68 Article  CAS  Google Scholar  * HG Xie _et al_. Molecular basis of ethnic differences in drug disposition and response _Annu Rev Pharmacol Toxicol_ 2001 41:


815–850 Article  CAS  Google Scholar  * HL McLeod, WE Evans . Pharmacogenomics: unlocking the human genome for better drug therapy _Annu Rev Pharmacol Toxicol_ 2001 41: 101–121 Article  CAS


  Google Scholar  * MM Ameyaw _et al_ . MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity _Pharmacogenetics_ 2001 11: 217–221


Article  CAS  Google Scholar  * International Human Genome Sequencing Consortium . Initial sequencing and analysis of the human genome _Nature_ 2001 409: 860–921 Article  Google Scholar  *


JC Venter _et al_ . The sequence of the human genome _Science_ 2001 291: 1304–1351 Article  CAS  Google Scholar  * GenBank (http://www.ncbi.nlm.nih.gov/GenBank) * MD Shriver _et al_.


Ethnic-affiliation estimation by use of populations—specific DNA markers _Am J Hum Gen_ 1997 60: 957–964 CAS  Google Scholar  * CM Stein _et al_ . Hypertension in black people: study of


specific genotypes and phenotypes will provide a greater understanding of interindividual and interethnic variability in blood pressure regulation than studies based on race


_Pharmacogenetics_ 2001 11: 95–110 Article  CAS  Google Scholar  * MA Rothstein, PG Epps . Ethical and legal implications of pharmacogenomics _Nat Rev Gen_ 2001 2: 228–231 Article  CAS 


Google Scholar  * National Institutes of Health _Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research_ 59 Fed Reg 14508, Mar 28 1994 * Centers for Disease


Control _Policy on the Inclusion of Women and Racial and Ethnic Minorities in Externally Awarded Research_ 60 Fed Reg 47947, Sep 15 1995 * M Foster, R Sharp, J Mulvihill . Pharmacogenetics,


race and ethnicity: social identities and individualized medical care _Therapeut Drug Monit_ 2001 23: 232–238 Article  CAS  Google Scholar  * AM Epstein, JZ Ayanian . Racial disparities in


medical care _New Eng J Med_ 2001 344: 1471–1473 Article  CAS  Google Scholar  * United States Department of Health & Human Services _The Initiative to Eliminate Racial and Ethnic


Disparities in Health_ (http://raceandhealth.hhs.gov) * J Gu _et al_ . Ethnic differences in poly CADP-ribose polymerase pseudogene genotype distribution association with lung cancer risk


_Carcinogenesis_ 1999 20: 1465–1469 Article  CAS  Google Scholar  * J Chen _et al_ . Racial differences in the use of cardiac catherization after acute myocardial infarction _New Eng J Med_


2001 344: 1443–1449 Article  CAS  Google Scholar  * S Satel . The indoctrinologists are coming _Atl Monthly_ 2001 287: 59–64 Google Scholar  * AJJ Wood . Racial differences in the response


to drugs—pointers to genetic differences _New Eng J Med_ 2001 344: 1393–1396 Article  Google Scholar  * Transcript, Interview with Dr Anne Taylor, CBS News: The Early Show, Mar 19, 2001


Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * University of Louisville School of Medicine, Louisville, KY, USA M A Rothstein * University of Houston Law Center, Houston,


TX, USA P G Epps Authors * M A Rothstein View author publications You can also search for this author inPubMed Google Scholar * P G Epps View author publications You can also search for this


author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to M A Rothstein. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Rothstein, M.,


Epps, P. Pharmacogenomics and the (ir)relevance of race. _Pharmacogenomics J_ 1, 104–108 (2001). https://doi.org/10.1038/sj.tpj.6500029 Download citation * Published: 07 September 2001 *


Issue Date: 01 February 2001 * DOI: https://doi.org/10.1038/sj.tpj.6500029 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link


Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative